Chemokine receptor CXCR4 expression is correlated with VEGF expression and poor survival in soft-tissue sarcoma

International Journal of Cancer

Volumn 124, Issue 8, 2009, Pages 1852-1859

  Oda, Yoshinao ^a   Tateishi, Naomi ^a   Matono, Hiroshi ^a   Matsuura, Suguru ^a   Yamamaoto, Hidetaka ^a   Tamiya, Sadafumi ^a   Yokoyama, Ryohei ^b   Matsuda, Shuichi ^a   Iwamoto, Yukihide ^a   Tsuneyoshi, Masazumi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

CXCR4; Soft tissue sarcoma; VEGF

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; KI 67 ANTIGEN; VASCULOTROPIN; CXCR4 PROTEIN, HUMAN; TUMOR MARKER; VASCULOTROPIN A;

ADOLESCENT; ADULT; ANGIOGENESIS; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; MALE; METASTASIS; MICROVASCULATURE; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOFT TISSUE SARCOMA; SURVIVAL RATE; TUMOR RECURRENCE; BIOSYNTHESIS; CELL SURVIVAL; GENE EXPRESSION REGULATION; METABOLISM; METHODOLOGY; MICROCIRCULATION; MORTALITY; SARCOMA; SOFT TISSUE TUMOR; TREATMENT OUTCOME;

ADULT; CELL SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROCIRCULATION; PROGNOSIS; RECEPTORS, CXCR4; SARCOMA; SOFT TISSUE NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 62449204461     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24128     Document Type: Article

References (43)

1. Muller A, Homey B, Sato H, Ge N, Catorn D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-56
2. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002;62:1832-1837. (Pubitemid 34408510)
3. Murakami T, Maki W, Cardones AR, Fang H, Tun Kyi A, Nestle FO, Hwang ST. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res 2002;62:7328-7334 (Pubitemid 36025256)
4. Ruffini PA, Morandi P, Cabioglu N, Altundag K, Cristofanilli M. Manipulating the chemokine-chemokine receptor network to treat cancer. Cancer 2007;109:2392-2404 (Pubitemid 46906457)
5. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23: 1011-1027 (Pubitemid 46202320)
6. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20:4368-4380 (Pubitemid 35266299)
7. Ferrara N, Hillan HP, Gerber W, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400. (Pubitemid 38618122)
8. Ferrara N. VEGF as a therapeutic target in cancer. Oncology 2005; 69:11-16. (Pubitemid 41680948)
9. Semenza GL. A new weapon for attacking tumor blood vessels. N Engl J Med 2008;358:2066-2067
10. Salcedo R, Wasserman K, Young HA, Grimm MC, Howard OMZ, Anver MR, Kleinman HK, Murphy WJ, Oppenheim JJ. Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells. In vivo neovascularization induced by stromal-derived factor-1a. Am J Pathol 1999;154: 1125-1135
11. Zagzag D, Lukyanov Y, Lan L, Ali MA, Esencay M, Mendez O, Yee H, Voura EB, Newcomb EW. Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab Invest 2006;86:1221-1232
12. Liang Z, Brooks J, Willard M, Liang K, Yoon Y, Kang S, Shim H. CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. Biochem Biophys Res Commun 2007;359:716-722 (Pubitemid 46908803)
13. Billadeau DD, Chatterjee S, Bramati P, Sreekumar R, Shah V, Hedin K, Urrutia R. Characterization of CXCR4 signaling in pancreatic cancer cells. Int J Gastrointest Canc 2006;37:110-119
14. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996;46:5-27. (Pubitemid 24035713)
15. Cormier JN, Xing Y, Feng L, Huang X, Davidson L, Gershenwald JE, Lee JE, Mansfield PF, Ross MI. Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: Chemotherapy-associated outcomes. J Clin Oncol 2004;22: 4567-4574
16. Laverdiere C, Hoang BH, Yang R, Sowers R, Qin J, Meyers PA, Huvos AG, Healey JH, Gorlick R. Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res 2005;11:2561-2567 (Pubitemid 40569454)
17. Libura J, Drukala J, Majka M, Tomescu O, Navenot JM, Kucia M, Marquez L, Peiper SC, Barr FG, Janowska-Wieczorek A, Ratajczak MZ. CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion. Blood 2002;100: 2597-2606
18. Strahm B, Durbin AD, Sexsmith E, Malkin D. The CXCR4-SDF1a axia is a critical mediator of rhabdomyosarcoma metastatic signaling induced by bone marrow stroma. Clin Exp Metastasis 2008;25:1-10.
19. Fletcher CDM, Unni KK, Mertens F, eds. World health organization classification of tumours. Pathology and genetics of tumours of soft tissue and bone. Lyon, France: IARC Press, 2002.
20. Guillou L, Coindre JM, Bonichon F, Nguyen BB, Terrier P, Collin F, Vilain MO, Mandard AM, Le Doussal V, Leroux A, Jacquemier J, Duplay H, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading system in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 1997;15:350-362
21. Fleming ID, Cooper JS, Henson DE. Soft tissue sarcoma. In: Fleming ID, Cooper JS, Henson DE, eds. American joint committee on cancer. cancer staging manual, 5th edn. Philadelphia, PA: Lippincott-Raven, 1998. 149-156
22. Oda Y, Yamamoto H, Tamiya S, Matsuda S, Tanaka K, Yokoyama R, Iwamoto Y, Tsuneyoshi M. CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: analysis within a group of patients, all of whom developed lung metastasis. Mod Pathol 2006;19:738-745
23. Kim J, Takeuchi H, Lam ST, Turner RR, Wang HJ, Kuo C, Foshag L, Bilchik AJ, Hoon DS. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk of recurrence and for poor survival. J Clin Oncol 2005;23:2744-2753 (Pubitemid 46179464)
24. Kim J, Mori T, Chen SL, Amersi FF, Martinez SR, Kuo C, Turner RR, Ye X, Bilchik AJ, Morton DL, Hoon DS. Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. Ann Surg 2006;244:113-120 (Pubitemid 44297455)
25. Salvucci O, Bouchard A, Baccarelli A, Deschênes J, Sauter G, Simon R, Bianchi R, Basik M. The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Res Treat 2006;97:275-283 (Pubitemid 43945757)
26. Diomedi-Camassei F, McDowell HP, De Ioris MA, Uccini S, Altavista P, Raschellà G, Vitali R, Mannarino O, De Sio L, Cozzi DA, Donfrancesco A, et al. Clinical significance of CXC chemokine receptor- 4 and c-Met in childhood rhabdomyosarcoma. Clin Cancer Res 2008;14:4119-4127
27. Perissinotto E, Cavalloni G, Leone F, Fonsato V, Mitola S, Grignani G, Surrenti N, Sangiolo D, Bussolino F, Piacibello W, Aglietta M. Involvement of chemokine receptor 4/ stroma derived factor 1 system during osteosarcoma tumor progression. Clin Cancer Res 2005;11: 490-497 (Pubitemid 40116871)
28. Yudoh K, Kanamori M, Ohmori K, Yasuda T, Aoki M, Kimura T. Concentration of vascular endothelial growth factor in the tumor tissue as a prognostic factor of soft tissue sarcomas. Br J Cancer 2001;84:1610-1615 (Pubitemid 32612491)
29. Potti A, Ganti AK, Foster H, Knox S, Hebert BJ, Tendulkar K, Sholes K, Koch M, Kargas S. Immunohistochemical detection of HER-2/neu, c-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas. Anticancer Res 2004;24:333-337 (Pubitemid 38279728)
30. DuBois S, Demetri G. Markers of angiogenesis and clinical features in patients with sarcoma. Cancer 2007;109:813-819 (Pubitemid 46333523)
31. Zhang L, Hannay JA, Liu J, Das P, Zhan M, Nguyen T, Hicklin DJ, Yu D, Pollock RE, Lev D. Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: implication for tumor growth, metastasis, and chemoresistance. Cancer Res 2006;66:8770-8778 (Pubitemid 44449194)
32. Chao C, Al-Saleem T, Brooks JJ, Rogatko A, Kraybill WG, Eisenberg B. Vascular endothelial growth factor and soft tissue sarcomas: tumor expression correlates with grade. Ann Surg Oncol 2001;8:260-267 (Pubitemid 32294808)
33. Potti A, Ganti AK, Tendulkar K, Sholes K, Chitajallu S, Koch M, Kargas S. Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role of overexpression in leiomyosarcoma. J Cancer Res Clin Oncol 2004;130:52-56 (Pubitemid 38161248)
34. Bachelder RE, Wendt MA, Mercurio AM. Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res 2002;62:7203-7206 (Pubitemid 36025239)
35. Kijowski J, Baj-Krzyworzeka M, Majka M, Reca R, Marquez LA, Christofidou-Solomidou M, Janowska-Wieczorek A, Ratajczak MZ. The SDF-1-CXCR4 axis stimulates VEGF secretion and activates integrins but does not affect proliferation and survival in lymphohematopoietic cells. Stem Cells 2001;19:453-466 (Pubitemid 32900088)
36. de Nigris F, Rossiello R, Schiano C, Arra C, Williams-Ignarro S, Barbieri A, Lanza A, Balestrieri A, Giuliano MT, Ignarro LJ, Napoli C. Deletion of Yin Yang 1 protein in osteosarcoma cells on cell invasion and CXCR4/angiogenesis and metastasis. Cancer Res 2008;68:1797-1808
37. Hasan J, Byers R, Jayson GC. Intra-tumoural microvessel density in human solid tumors. Br J Cancer 2002;86:1566-1577 (Pubitemid 34628110)
38. Pakos EE, Goussia AC, Tsekeris PG, Papachristou DJ, Stefanou D, Agnantis NJ. Expression of vascular endothelial growth factor and its receptor. KDR/Flk-1, in soft tissue sarcomas. Anticancer Res 2005; 25:3591-3596
39. West CC, Brown NJ, Mangham DC, Grimer RJ, Reed MW. Microvessel density does not predict outcome in high grade soft tissue sarcoma. Eur J Surg Oncol 2005;31:1198-1205 (Pubitemid 41819208)
40. Ohsawa M, Tomita Y, Kuratsu S, Kanno H, Aozasa K. Angiogenesis in malignant fibrous histiocytoma. Oncology 1995;52:51-54
41. Miracco C, Montesco MC, Santopietro R, Spina D, d'Amore ES, Tosi P, Ninfo V. Proliferative activity, angiogenesis, and necrosis in peripheral nerve sheath tumors: a quantative evaluation of prognosis. Mod Pathol 1996;9:1108-1117
42. Kawauchi S, Fukuda T, Tsuneyoshi M. Angiogenesis does not correlate with prognosis or expression of vascular endothelial growth factor in synovial sarcoma. Oncol Rep 1999;6:959-964
43. Mentzel T, Brown LF, Dvorak HF, Kuhnen C, Stiller KJ, Katenkamp D, Fletcher CD. The association between tumor progression and vascularity in myxofibrosarcoma and myxoid/round cell liposarcoma. Virchows Arch 2001;438:13-22. (Pubitemid 32128185)